Silverback Therapeutics, Inc. SBTX
52-week range unavailable
- Open
- 5.82
- Prev close
- 5.87
- Mkt cap
- 550.43M
- Vol
- 116.69K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.82
- High
- 6.15
- Forward P/E
- -2.76
- Beta
- 0.00
- Short ratio
- 5.20
- Inst. own
- 78.61%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2022
- 50-d avg
- 5.39
- 200-d avg
- 4.37
- 1y target
- 5.00
MAX chart
Chart tools
Chart is warming up
The all-time price history for SBTX has not been loaded yet. Try again in a moment.
Altman Z-Score
-1.83 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
P/E -3.4×
P/S 6.9×
P/B 5.1×
P/FCF -3.4×
EV/EBITDA 393×
EV/Sales 6.4×
FCF Yield -29.6%
Gross Margin 0.0%
Operating Margin -212.9%
Net Margin -203.3%
ROE -149.9%
ROIC -62.2%
ROA -52.3%
Revenue -5.5%
Operating Income -5720.6%
EPS (diluted) -2327.9%
Free Cash Flow -1418.5%
Current Ratio 7.3×
Quick Ratio 7.1×
Debt / Equity 0.0×
Net Debt / EBITDA -30.2×
Interest Coverage 69.0×
Dividend Yield 0.0%
Payout Ratio 0.0%
Annual · latest fiscal year ends 2025-12-31